Bollywood’s beloved Salman Khan recently astonished fans and the public alike when he revealed that, in addition to battling a brain aneurysm and arteriovenous malformation (AVM), he lives with trigeminal neuralgia (TN), a condition so painful it’s earned the chilling nickname “suicide disease.” This disclosure has thrown a spotlight on a rare but devastating neurological disorder that turns even everyday actions into moments of torture. Through his admission, Salman Khan has unwittingly become an advocate, prompting a deeper conversation around TN: its causes, symptoms, triggers, impact on daily life, and the evolving landscape of treatment in India.

At its core, trigeminal neuralgia is a disorder of the trigeminal nerve i.e. the fifth cranial nerve responsible for facial sensation. When functioning normally, this nerve transmits sensory information from the face to the brain. But in TN, a misfire occurs. A blood vessel or other compressive force presses on the nerve near the brainstem, causing sudden, electric shock-like jolts often described as shooting pain, in areas like the jaw, cheeks, lips, or around the eyes. One moment you’re brushing your teeth; the next, a lightning bolt of pain shocks half your face.

The hallmark of TN is its unpredictability. The pain typically lasts from a few seconds to several minutes, but these agonising bursts can repeat repeatedly throughout the day. Over time, they may cluster in cycles, with weeks or months of remission giving way to sudden flare-ups that cripple daily life. Light movements like buttoning a shirt, speaking, or even a puff of air can trigger debilitating pain.

Despite its unpredictable nature, TN shares common triggers: chewing, shaving, tooth brushing, speaking, and sudden changes in temperature or touch. Patients often adapt their routines out of fear. Many avoid smiling, eating freely, or social interactions, leading to isolation, anxiety, and even depression. Some research points to TN’s psychological toll, with sufferers showing elevated rates of depression and suicidal ideation giving rise to its chilling nickname, the “suicide disease.”

TN affects roughly 1 in 8,000 people annually, with women over the age of 50 being most at risk, and a higher prevalence in those with multiple sclerosis. While primary TN stems from vascular compression, secondary forms may result from underlying conditions like facial trauma, tumors, strokes, or diseases that damage the myelin sheath or insulating layer around nerves.

Diagnosing TN requires both clinical insight and imaging. Neurologists rely on detailed patient histories and symptom descriptions particularly the characteristic “electric shock” pain. Brain MRI may help rule out tumour causes or vascular compression, while advanced imaging ensures precise diagnosis.

Treatment for TN began decades ago with anticonvulsant medications, such as carbamazepine and oxcarbazepine, which reduce nerve excitability and block pain signals. These remain first-line therapies and are often highly effective, though they may cause side effects like dizziness or fatigue.

For patients who don’t find relief or can’t tolerate medications, surgical options exist. Microvascular decompression (MVD), pioneered in the 1960s, is considered the gold standard. In which repositioning or padding a compressive vessel to relieve nerve pressure takes place. While invasive and requiring brain surgery, success rates are high: about 82% achieve complete relief, with 98% experiencing significant improvement. Long-term relief is observed in nearly 70% over a decade.

Less invasive alternatives have emerged, such as Gamma Knife radiosurgery which is a form of focused radiation that disables the nerve root. Though pain relief onset is slower, response rates are good. Other options include nerve blocks, Botox injections, and complementary therapies like acupuncture, biofeedback, meditation, or yoga.

In India, specialists at hospitals like Apollo, Fortis, Medanta, and Max provide modern TN care, leveraging both pharmacological and surgical strategies. However, access remains uneven. Many in tier 2 or rural regions lack specialist care and rely on general practitioners, delaying accurate diagnosis and effective treatment. Awareness is often limited, and the hidden nature of TN and its triggers can lead patients to believe they have dental or jaw issues, rather than a nerve disorder.

Salman Khan’s decision to openly discuss his condition has brought TN into mainstream conversation. His resilience exemplifies how individuals with TN navigate personal and professional worlds daily. It also highlights the urgent need for public education: a light breeze or meal shouldn’t carry the threat of agony. But for someone with TN, such fears drive avoidance, distrust of medical systems, and emotional distress.

His narrative highlights three key imperatives: early recognition, access to specialised care, and removing stigma. Given TN’s rarity and symptomatic overlap with dental pain, misdiagnosis is common. Educating general practitioners and dentists on trigeminal neuralgia could significantly reduce delays in correct diagnosis. Meanwhile, expanding access to neurosurgical care even with minimally invasive treatments like Gamma Knife can relieve suffering for patients nationwide. Finally, normalising discussions around TN helps those suffering feel less isolated and more empowered to seek help.

Salman’s admission may just be the spark needed to transform care. Imagine a community where routine health checks include simple nerve assessments for older adults. Where neurologists are available more widely, both physically and telephonically. Where patients gain not only treatment, but emotional support, pain management guidance, and conservation of mental well‑being. Early medical studies indicate that nearly 80% of TN patients improve with initial treatment. Timely therapy can transform lives of those once asked to live in constant fear of a tooth touch.

In the global context, TN remains a condition with no “cure” but it can be managed. Its unpredictable attacks can cease, cycles may settle into remission, and many go years without severe symptoms. But treatment requires vigilance. Discontinuing medication can cause relapse. Surgery is not always successful, and side effects though rare must be weighed carefully. Continuous follow‑up and adjusting therapies become essential. In India, where chronic care models are still evolving, this requires investment in neurology services and patient education focused on long-term outcomes.

Bollywood’s biggest star, by sharing his suffering, has equipped TN patients across India with a voice and a chance of renewed hope. His example demands a response, not of sympathy, but of action. We must prioritise awareness campaigns, healthcare training programs, and accessible specialist services all aimed at delivering efficient relief. Salman’s journey also serves as a counter‑narrative to stardom’s privilege: even the strong, the famous, and the adored battle unseen fights, and sometimes most bravely in public.

In the end, trigeminal neuralgia is more than neural discharge or pain triggers. It’s a disease of perception and reality hidden until lightning strikes the face. But now, with insight, understanding, and timely treatment, we can dim TN’s lethal reputation. Let’s turn “suicide disease” into “manageable disease,” one patient at a time.